GlassScriptPhysician profile
Scott J Anzalone
NPI 1275544579
$852.09
in general payments reported to CMS, 2019-2025
25 companies · $91.14 in 2025
The $91.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $28.79 · 2021: $110 · 2022: $186 · 2023: $31.96 · 2024: $257 · 2025: $91.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $242.76 | 2021-2025 | Qelbree |
| Novo Nordisk INC | $73.93 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $71.93 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $68.45 | 2019-2022 | |
| Abbvie INC. | $39.53 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $33.78 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $30.15 | 2020-2021 | |
| Astellas Pharma US INC | $27.62 | 2024 | Veozah |
| Abbott Laboratories | $24.28 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $21.01 | 2024 | Voquezna |
| Dexcom, INC. | $18.63 | 2023 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $17.59 | 2024 | Daybue |
| Sunovion Pharmaceuticals INC. | $17.07 | 2019 | |
| Amgen INC. | $16.36 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.70 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $15.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.85 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $13.13 | 2019 | |
| Medtronic, INC. | $12.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Anzalone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.